Pictet Asset Management Holding SA Buys 135,969 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Pictet Asset Management Holding SA boosted its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 16.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 972,293 shares of the company's stock after buying an additional 135,969 shares during the period. Pictet Asset Management Holding SA owned 1.99% of Enliven Therapeutics worth $21,877,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in shares of Enliven Therapeutics by 10.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company's stock valued at $6,520,000 after purchasing an additional 24,043 shares during the period. The Manufacturers Life Insurance Company raised its position in Enliven Therapeutics by 25.6% in the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company's stock worth $441,000 after acquiring an additional 3,518 shares in the last quarter. FMR LLC lifted its holdings in Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company's stock valued at $160,804,000 after acquiring an additional 601,611 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Enliven Therapeutics by 12.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company's stock valued at $668,000 after purchasing an additional 2,944 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Enliven Therapeutics in the 3rd quarter worth approximately $2,539,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ELVN shares. HC Wainwright raised their target price on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, March 21st. BTIG Research initiated coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a "buy" rating and a $42.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of "Buy" and an average price target of $38.75.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock traded down $1.34 during midday trading on Friday, reaching $18.69. The stock had a trading volume of 516,094 shares, compared to its average volume of 280,337. Enliven Therapeutics, Inc. has a twelve month low of $15.96 and a twelve month high of $30.03. The firm has a market cap of $915.88 million, a price-to-earnings ratio of -9.84 and a beta of 1.03. The firm's fifty day simple moving average is $21.03 and its two-hundred day simple moving average is $23.64.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other news, CEO Samuel Kintz sold 12,500 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the sale, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at $20,629,865.36. This trade represents a 1.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $21.59, for a total value of $70,167.50. Following the completion of the sale, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at approximately $280,670. The trade was a 20.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,784 shares of company stock valued at $1,582,696 over the last three months. 29.20% of the stock is owned by corporate insiders.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.